Current Report Filing (8-k)
2020年4月9日 - 9:46PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 8, 2020
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
Nevada
|
|
001-38543
|
|
26-1265381
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
400
Water Street, Suite 200, Rochester, MI
|
|
48307
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 248.651.6568
|
|
|
|
(Former
name or former address, if changed since last report)
|
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
symbol
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
OPRX
|
|
Nasdaq
Capital Market
|
SECTION
8 – Other Events
Item 8.01 Other Events
On
April 8, 2020, we issued a press release announcing that we received the ranking of #282 by the Financial Times’ 2020 list
of The Americas’ 500 Fastest-Growing Companies. A copy of the press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K.
The
information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
SECTION
9 – Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
OptimizeRx Corporation
|
|
|
|
/s/ Douglas Baker
|
|
Douglas Baker
|
|
Chief Financial Officer
|
|
|
|
Date April 9, 2020
|
|
2
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024